Tg Therapeutics (TGTX) Operating Leases (2019 - 2026)

Tg Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Operating Leases fell 16.09% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (down 16.09% YoY), while the FY2025 annual figure was $7.0 million, down 13.67% from the prior year.
• Operating Leases for Q1 2026 stood at $6.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Operating Leases was $10.6 million in Q3 2022, with the low at $6.6 million in Q1 2026.
• The 5-year median for Operating Leases is $9.0 million (2024), against an average of $8.8 million.
• The sharpest annual moves came in 2022 and 2026: Operating Leases gained 5.61% in 2022, then slipped 16.09% in 2026.
• Tg Therapeutics' Operating Leases stood at $10.3 million in 2022, then slipped by 10.76% to $9.2 million in 2023, then slipped by 11.89% to $8.1 million in 2024, then fell by 13.67% to $7.0 million in 2025, then fell by 6.07% to $6.6 million in 2026.
• Business Quant data shows TGTX's Operating Leases at $6.6 million in Q1 2026, $7.0 million in Q4 2025, and $7.3 million in Q3 2025.